Table 1 Characteristics of ICC patient (N = 28), treatment (N = 23) and lesion (N = 34) population at baseline
From: Individualised dosimetry and safety of SIRT for intrahepatic cholangiocarcinoma
Characteristic | N (%) unless indicated otherwise |
|---|---|
Age in years, median (range) | 67 (42–81) |
Sex | |
Male | 8 (44%) |
Female | 10 (56%) |
BMI, median (range) | 27 (21–35) |
Hepatic tumour burden (%)a, median (range) | 18 (1–42) |
Extrahepatic metastasesb | 10 (56%) |
Prior therapies | |
Chemotherapyb | 13 (72%) |
Hepatic resection | 2 (11%) |
TACEc to liver | 3 (17%) |
Radiotherapy | 2 (11%) |
Cirrhosis present | 1 (6%) |
Treatment to whole liver | 12 (67%) |
Prescribed amount of 90Y for treatment in GBq, median (range) | 1.5 (0.6–3.0) |
Time to follow-up FDG PET/CT in days, median (range) | 51 (42–79) |
Lesion volume (cc), median (range) | 143 (11–1272) |
Lesion SUVmax, median (range) | 11.5 (5.0–26.4) |
Lesion TLG, median (range) | 598 (54–8007) |
Overall survival in months, median (range)d | 6.5 (4.4–19.9) |